PRIMARY STUDY

Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia

Key Findings:  Resulting data suggest that pharmacological treatments with CB2 agonists (i.e. HU-308) may represent a novel treatment strategy in PD patients suffering from L-dopa induced dyskinesia (a relatively common and debilitating side-effect of the drug).